Background-The clinical significance of incomplete coronary revascularization (ICR) after percutaneous coronary intervention in patients with acute coronary syndromes is unknown. Methods and Results-We performed quantitative angiography of the entire coronary tree in 2954 patients with acute coronary syndromes in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. ICR was variably defined if any lesion with diameter stenosis (DS) cutoffs ranging from Ն30% to Ն70% with reference vessel diameter Ն2.0 mm remained after percutaneous coronary intervention. The primary outcome was 1-year composite rate of major adverse cardiac events (death, myocardial infarction, or ischemia-driven unplanned revascularization). With the use of DS cutoffs Ն30%, Ն40%, Ն50%, Ն60%, and Ն70%, the prevalence of ICR after percutaneous coronary intervention was 75%, 55%, 37%, 25%, and 17%, respectively. The 1-year major adverse cardiac event rate was increased among patients with ICR using all of the DS cutoffs. ICR (Ն50% DS) was associated with higher 1-year rates of myocardial infarction (12.0% versus 8.2%; hazard ratio, 1.50; 95% confidence interval, 1.18 -1.89; Pϭ0.0007) and ischemia-driven unplanned revascularization (15.7% versus 10.2%; hazard ratio, 1.58; 95% confidence interval, 1.28 -1.96; PϽ0.0001), with a trend toward increased mortality (3.1% versus 2.2%; hazard ratio, 1.43; 95% confidence interval, 0.90 -2.27; Pϭ0.13). By multivariable analysis, ICR (Ն50% DS) was an independent predictor of 1-year major adverse cardiac events (hazard ratio, 1.36; 95% confidence interval, 1.12-1.64; Pϭ0.002). The impact of ICR on major adverse cardiac events was similar regardless of chronic total occlusion presence, but it was more pronounced with a greater number of nonrevascularized lesions. Conclusions-Depending on the threshold of percent DS, ICR was present in 17% to 75% of patients with acute coronary syndromes after percutaneous coronary intervention. Regardless of the threshold, ICR was strongly associated with 1-year myocardial infarction, ischemia-driven unplanned revascularization, and major adverse cardiac events. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00093158. (Circulation. 2012;125:2613-2620.)
T he benefits of achieving complete revascularization (CR) rather than incomplete revascularization (ICR) in patients undergoing coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) remain controversial. An absence of randomized clinical trial data, varying definitions of CR, and substantial baseline differences between patients in whom CR is versus is not achieved are all contributory factors fuelling the debate. between patients with 2, 3, or Ͼ3 grafts, 4 and no differences in survival between CR and ICR were demonstrated in the Bypass Angioplasty Revascularization Investigation (BARI) trial. 5 Recent surgical studies have also called into question the importance of CR, possibly attributed to advances in surgical technique (routine use of the left internal mammary artery, off-pump CABG, and minimally invasive surgical approaches). 6, 7 Even less well characterized is the necessity of CR after PCI. Analysis of the New York State PCI database demonstrated increased long-term mortality with ICR, 8, 9 and in the Arterial Revascularization Therapies Study (ARTS), patients with ICR after PCI had a higher incidence of subsequent CABG procedures. 10 However, a recent study from the large Asan Medical Center multivessel registry reported that selective ICR after either PCI or CABG does not impair long-term clinical outcomes. 11 No prior study has specifically examined the importance of ICR in patients with ACS. Although CR should intuitively reduce overall ischemic burden (the extent of which has been associated with subsequent death and myocardial infarction [MI], even in low-risk patients 12 ), revascularization of nonculprit territories in addition to the primary culprit lesion in ACS may expose patients to an increased risk of periprocedural complications and late restenosis and stent thrombosis compared with a strategy of selective ICR. 13 Moreover, the definition of ICR has varied in all prior studies and has relied on visual angiographic estimation of lesion severity; no prior study has used quantitative coronary angiography (QCA) to independently determine the prevalence of ICR or to examine the prognostic impact of different thresholds of angiographic diameter stenosis (DS) severity used to define ICR. We therefore sought to examine the role of ICR using different angiographic thresholds on the 1-year clinical outcomes of patients with non-ST-segment-elevation ACS (NSTEACS) treated with PCI from the large-scale Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
Methods

Study Protocol
The ACUITY trial design has been described previously. 14 Briefly, ACUITY was a multicenter, prospective, randomized trial of 13 819 patients with moderate-and high-risk NSTEACS treated with an early invasive management strategy. Patients were randomly assigned before coronary angiography to heparin (unfractionated or enoxaparin) plus a glycoprotein IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin monotherapy. Angiography was performed in all patients within 72 hours of randomization. Depending on coronary anatomy and the suitability of lesions for revascularization, patients were triaged to PCI, CABG, or medical management. In patients who were triaged to PCI, selection of stent type (bare metal or drug-eluting) was at the operator's discretion. Dual antiplatelet therapy with aspirin and clopidogrel was recommended for at least 1 year. All major adverse events were adjudicated by an independent clinical events committee blinded to treatment assignment.
Patients, Angiographic Analysis, and Outcome Measures
As previously described, QCA of the entire coronary tree was performed in 6921 patients enrolled in ACUITY (88% of all 7851 US patients), including 3826 patients in whom PCI was performed (90% of all 4254 US patients who underwent PCI). An additional 872 patients with prior CABG were excluded, resulting in a total of 2954 patients with NSTEACS treated with PCI included in the present study. QCA was performed on the baseline and post-PCI angiograms at an independent angiographic core laboratory (Cardiovascular Research Foundation, New York, NY) by investigators blinded to treatment assignment and clinical outcomes as part of a formal ACUITY substudy. 15 ICR was variably defined to be present if any lesion with a final DS ranging from Ն30% to Ն70% (in 10% increments) with a reference vessel diameter (RVD) Ն2.0 mm by QCA was left untreated after PCI in any epicardial coronary artery. The primary outcome measure was the 1-year composite rate of major adverse cardiac events (MACE: all-cause death, MI, or ischemia-driven unplanned repeat revascularization), as adjudicated by an independent clinical events committee blinded to treatment allocation and index procedural angiographic results. The definitions for death, MI, and ischemia-driven unplanned repeat revascularization have previously been reported. 14 Because the 1-year MACE rates were not significantly different in the 3 randomized arms of ACUITY, 16 all 3 groups were pooled for the present study.
Statistical Analysis
Categorical variables were compared by the 2 or Fisher exact test as appropriate. Continuous variables were compared by the Wilcoxon rank-sum test. One-year event rate estimates were determined with Kaplan-Meier methodology and compared by the log-rank test.
Stepwise Cox multivariable regression analyses were performed to determine whether ICR was an independent predictor of MACE. The initial Cox model was built with the use of stepwise methods and included the following candidate variables: age, male sex, diabetes mellitus (treated with or without insulin), current smoking, hypertension, hyperlipidemia, previous MI, previous PCI, renal dysfunction, baseline cardiac biomarker (creatinine phosphokinase-MB or troponin) elevation, baseline ST-segment deviation Ն1 mm, white blood cell count, hemoglobin level, left anterior descending artery treatment, presence of double-vessel or triple-vessel coronary artery disease, number of treated PCI lesions per patient, and type of stent (drug-eluting versus bare metal stent). After the significant independent baseline predictors were identified, the Cox model was rebuilt to include the ICR/CR variable. The sensitivity and specificity of ICR as defined by varying percent DS (in 1% absolute increments) for MACE were assessed by plotting sensitivity and specificity versus percent DS. Statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC). A value of PϽ0.05 was considered statistically significant, and all P values were 2 sided.
Results
Prevalence and Correlates of ICR
With QCA DS cutoffs of Ն30%, Ն40%, Ն50%, Ն60%, and Ն70%, the prevalence of ICR after PCI was 75% (nϭ2203), 55% (nϭ1628), 37% (nϭ1103), 25% (nϭ737), and 17% (nϭ502), respectively. With a DS cutoff of Ն50% used to define ICR, 566 patients (19.2%) had untreated lesions in treated vessels, and 713 patients (24.2%) had untreated lesions in untreated vessels. ICR (DS Ն50% threshold) was associated with older age, increased body weight, hypertension, renal insufficiency, baseline cardiac biomarker elevation, higher Thrombolysis in Myocardial Infarction risk score, and more triple-vessel disease ( Table 1 ). ICR was also associated with a fewer number of lesions treated with PCI per patient, less left anterior descending artery disease treated by PCI, and less drug-eluting stent implantation.
Relationship Between ICR and Clinical Outcomes
Regardless of the percent DS cutoff used to define ICR after PCI, ICR was significantly associated with the more frequent occurrence of MACE at 1 year ( Table 2 ). The higher the threshold of percent DS required to define ICR was, the greater the absolute MACE rate in the ICR group was, and the greater the hazard ratio (HR) for MACE was for patients in whom ICR was present. However, the sensitivity to detect 1-year MACE was increased with lower percent DS cutoff values for ICR, whereas specificity was increased with higher percent DS cutoff values for ICR. From the plot of sensitivity versus specificity, the optimal QCA percent DS cutoff to define ICR to balance sensitivity and specificity was Ϸ44% ( Figure 1 ). Table 3 and Figure 2 ). ICR was also associated with higher post-hospital discharge to 1-year rates of MI (5.1% versus 3.5%; HR, 1.48; 95% CI, 1.01-2.16; Pϭ0.04) and ischemia-driven unplanned repeat revascularization procedures (13.4% versus 9.3%; HR, 1.45; 95% CI, 1.15-1.82; Pϭ0.002), with a trend toward increased mortality (2.7% versus 2.0%; HR, 1.35; 95% CI, 0.82-2.22; Pϭ0.23). After adjustment for potential confounders, ICR using the DS Ն50% threshold was an independent predictor of 1-year MACE ( Table 4 ). Other covariates independently associated with MACE included renal insufficiency, prior PCI, and a greater number of treated lesions by PCI.
Impact of a Chronic Total Occlusion and the Number of Nonrevascularized Lesions
Of the 1103 patients with ICR (using a threshold DS Ն50%), 378 (34.3%) had a chronic total occlusion and 725 (65.7%) did not. Among patients with ICR, the MACE rates in those with versus without a chronic total occlusion were not significantly different, but each was significantly higher than in patients with CR (Table 5 ). Of the 1103 patients with ICR (using a threshold DS Ն50%), 729 (66.1%) had a single nonrevascularized lesion and 374 (33.9%) had Ն2 nonrevascularized lesions. The 1-year MACE rates were lowest in patients with CR, intermediate in those with 1 nonrevascularized lesion, and highest in those with Ն2 nonrevascularized lesions ( Table 5 ). Figure 1 . Sensitivity and specificity curves for each percentage diameter stenosis (DS) in 1% increments used to define incomplete revascularization (ICR) for the occurrence of 1-year major adverse cardiac events (MACE). Sensitivity to detect 1-year MACE is increased with lower percent DS cutoff values for ICR, whereas specificity is increased with higher percent DS cutoff values for ICR. The overlap point of the 2 curves represents the "optimal" threshold that balances sensitivity and specificity to predict subsequent MACE in non-ST-segment-elevation acute coronary syndromes. This occurs at a DS of Ϸ44% determined by quantitative coronary angiography after percutaneous coronary intervention in a coronary artery with reference vessel diameter Ն2.0 mm. This is roughly equivalent to a visually estimated DS of 55% to 60%. The area under the curve for the DS-MACE receiver-operator characteristic curve analysis was 0.56. 
Discussion
The principal findings from the present analysis of the ACUITY trial in moderate-and high-risk patients with NSTEACS are the following. First, the prevalence of ICR after PCI varied widely from 17% to 75% of patients, depending on the threshold of angiographic percent DS used to define ICR. Second, defining ICR with a greater percent DS threshold decreased the sensitivity but increased the specificity for 1-year MACE and was associated with greater rates of MACE in patients with ICR. Third, regardless of the threshold percent DS used to define ICR, the presence of ICR after PCI was strongly associated with 1-year MACE, driven by increased rates of MI and ischemia-driven unplanned repeat revascularization in patients with ICR, with numerically greater but nonsignificantly different rates of mortality.
Prior studies have reported a variable prevalence and prognostic impact of ICR after revascularization procedures. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] There may be several reasons for these inconsistencies. First, there is no universally accepted definition of ICR. Most commonly, ICR has been defined anatomically on the basis of coronary angiography. One study-proposed definition of ICR was an untreated lesion Ն50% DS with RVD Ն1.5 mm, 9 whereas another required Ն70% DS for ICR. 17 A third study used numerous different definitions for ICR (Ն50% DS with RVD Ն1.5 mm, Ն50% DS with RVD Ն2.5 mm, and Ն50% DS in a proximal artery). 11 prior studies used visual assessment to define lesion severity, which is known to have greater interobserver variability and to overestimate percent DS compared with QCA. 18 Second, different patient populations, end-point definitions, and levels of monitoring and other differences in study methodologies (including blinding) may explain the discordance between earlier studies. Third, the assessment of CR versus ICR is based on what happened at the time of surgery (by operative report) or PCI (by angiographic review) and does not take into account immediate and late graft attrition or subsequent in-stent restenosis or stent thrombosis. Fourth, not all prior studies have used multivariable analysis to correct for imbalances between patients with versus without ICR, and those that have were mostly registry studies in which the extent and quality of data collection and verification are often suboptimal. Importantly, in virtually every study comparing CR and ICR, patients in the ICR group have been sicker, and although multivariable analyses can adjust for this bias when overt, unmeasured residual confounders cannot be accounted for.
The present study, drawn from the detailed database of the large-scale, multicenter, prospective ACUITY trial, in which all end point events were monitored and adjudicated by an independent committee blinded to the degree of CR, thus overcomes many of these limitations. Moreover, the ACUITY angiographic substudy is the largest core laboratory-based QCA study to date, and the performance of QCA of the entire coronary tree in this substudy (rather than just the lesions treated with PCI) offered the unique opportunity to assess the extent to which ICR after PCI in NSTEACS is indeed a predictor of MACE during the follow-up period. The results of this study demonstrate that regardless of the percent DS threshold used to define ICR, the presence of angiographic ICR is a strong independent predictor of 1-year MACE (driven by increased rates of MI and ischemia-driven unplanned repeat revascularization), even after adjustment for the number of diseased epicardial coronary arteries. In support of this observation, the greater the number of nonrevascularized lesions present was, the greater the 1-year rate of MACE was (although the presence of a chronic total occlusion was not a significant predictor of MACE in patients with ICR).
The present study suggests that using a QCA DS of Ϸ44% after PCI (with RVD Ն2.0 mm) to define ICR might optimize the sensitivity and specificity to predict subsequent MACE in NSTEACS. This roughly corresponds to a visually assessed DS of 55% to 60%. The present study, however, did not evaluate whether the prognostic accuracy of ICR for subse-quent MACE would have been even greater had lesion severity been assessed on a functional or physiological level rather than strictly an anatomic basis. In the Fractional Flow Reserve Versus Angiography in Multivessel Evaluation (FAME) trial, only 35% of lesions with a visually estimated angiographic DS of 50% to 70% were functionally significant (fractional flow reserve Յ0.80), 19 and deferred lesions with a fractional flow reserve Ͼ0.80 had very low rates of MACE during 2-year follow-up. 20 Additionally, simple anatomic measures of ICR fail to consider plaque burden and composition, which, as assessed by radiofrequency intravascular ultrasound, have been shown to predict MACE of untreated lesions in ACS patients independently of angiographic lesion severity. 21 However, 3-vessel intravascular ultrasound and fractional flow reserve of nonculprit stenoses are not routinely performed in patients with ACS. Therefore, an enhanced understanding of the role of angiographic ICR after PCI in ACS, as detailed in the present report, has practical clinical implications for patient care and future trial design.
Importantly, although all patients in the present study from ACUITY had a revascularization procedure, the term ICR should not be interpreted to imply that converting such patients to CR with additional PCI would necessarily improve their prognosis. Although a certain proportion of future MACE events may arise from angiographically untreated lesions, the presence of ICR may also reflect a greater degree of underlying coronary atherosclerosis. As shown in the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study, 21 unanticipated future nonculprit lesion-related adverse events often arise from angiographically unapparent lesions, the severity of which is appreciated only by intravascular ultrasound imaging. Moreover, approximately half of the ischemiadriven repeat revascularization events in the present study arose from originally treated culprit lesions, which were more common in patients with ICR (also signifying more extensive coronary atherosclerosis). Thus, a better term for ICR might be residual atherosclerosis, although we have retained the widely used original term to acknowledge its historical context.
Limitations
Our study has several limitations. First, the ACUITY trial was not specifically designed to compare a strategy of CR versus ICR in patients with ACS undergoing PCI. As a post hoc analysis from a prospective, randomized trial, the results should be considered hypothesis generating. Although we attempted to correct for potential confounders using a multivariable model, residual confounding may persist, and the association between ICR and subsequent MACE in the present report does not prove causality. Similarly, the prespecified ACUITY angiographic substudy was restricted to US sites. Given geographic differences in patient characteristics and practice patterns, it is possible that the impact of ICR might vary in different countries. Second, we did not prospectively collect the operator's intention for CR versus ICR or the reasons for ICR of selected lesions. This raises the possibility of confounding by indication; ie, the success or ease of the PCI procedure may itself be associated with the decision to proceed with CR versus ICR and may be associated with the likelihood of MACE. Indeed, visual assessment of the Kaplan-Meier curves reveals that the increase in MACE in patients with ICR may be explained by events occurring both early in the periprocedural period (MI and unplanned revascularization) and late during 1-year follow-up (death, MI, and unplanned revascularization). Third, we also have not considered whether the model could be strengthened by considering other angiographic characteristics such as lesion length or RVD. Fourth, operators may be more prone to perform repeat revascularization in patients in whom revascularization was known to be incomplete. Nonetheless, these do represent real procedures with attendant risks and cost. Fifth, follow-up in ACUITY was completed at 1 year; thus, we could not evaluate the relationship between ICR and events beyond this time point. Sixth, routine postprocedural fractional flow reserve measurements and follow-up exercise testing were not performed in ACUITY; therefore, we cannot directly assess the extent to which residual ischemia explains the relationship between ICR and subsequent adverse outcomes. Finally, the results of this study apply only to patients with NSTEACS. It is unknown whether the impact of ICR would be similar or more or less marked in patients with stable ischemic heart disease and ST-segment-elevation MI.
Clinical Implications and Future Directions
The present study raises the question of whether CR should be the goal of PCI in ACS. In the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy, ischemia reduction of Ն5% and a low level of residual ischemia after either PCI or optimal medical therapy in patients with stable ischemic syndromes were associated with a lower risk of death or MI during follow-up. 12 Several observational single-center studies have also reported lower rates of MACE in patients with NSTEACS and multivessel disease who underwent CR with drug-eluting stents compared with culprit lesion revascularization only. 22, 23 However, none of these studies were randomized, and it is possible that residual confounding (eg, the extent of atherosclerosis) explains the worse prognosis in patients with ICR. Treating additional nonculprit lesions in ACS to achieve CR would likely entail some excess risk of procedural complications and additional cost. Moreover, the adverse prognosis of patients with ICR may be due in part to more extensive diffuse coronary atherosclerosis, not just to angiographically evident untreated focal lesions. Further-more, whether residual focal lesions in patients with NSTEACS should be treated during the index PCI or during a second staged procedure is unknown. In this regard, several observational studies in patients with ST-segment elevation MI have suggested that nonculprit lesion treatment during the index primary PCI may be associated with increased mortality. 24, 25 A large-scale, randomized trial is thus warranted and required to determine whether a CR strategy (either single procedure or staged) is capable of reducing MACE compared with a selective ICR approach (whether angiographically or functionally guided) in ACS.
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